Shingles jab may reduce risk of heart attack, pioneering research reveals | Vaccines and immunisation
According to the first work of the type, zone vaccine can reduce your risk of heart attack or stroke by 20%.
Zona is a common situation that causes a worldwide painful rash and affects millions that can cause serious problems such as deafness, long -term pain and blindness. It is more likely to cause serious problems in old age groups.
Most countries tend to recommend the vaccine only to elderly people or immunosuprese adults, but findings suggest that they may have cardiovascular protective effects in adults under the age of 18.
The results of the world’s first global systematic examination and commodity analysis show that JAB is associated with an important risk of cardiovascular event.
Having a zone jab was associated with 18% lower stroke or heart attack in adults. There was a 16% decrease in the risk of cardiovascular event in adults aged 50 years and older.
Data will be presented to thousands of cardiologists at the annual meeting this weekend. European Cardiology Association The world’s largest cardiology conference in Madrid.
Dr. Charles Williams, the author of the study and the global assistant medical director in GSK, said, ık We have currently looked at the existing evidence and found that vaccination against Herpes Zoster is associated with lower cardiovascular incident risk, such as heart attacks or strokes.
“To find out if this association cannot be attributed to a effect on herpes zoster vaccination, more research should be studied.”
Global systematic compilation was carried out using three scientific literature databases and observative studies were carried out in phase 3 randomized controlled studies and an observational studies evaluating the effect of a commodity analysis and herpes zoster vaccination on cardiovascular events.
Zona jab is usually taken only once and typically applied at two doses of two months.
A total of 19 studies were included in the examination. Eight observational work and a randomized controlled study met the criteria of involving jab to examine the impact of cardiovascular events.
Vaccination is seen as an effective measure not only against specific infections, but also for the prevention of cardiovascular disease or events.
“These results support an increasing group of evidence showing that vaccines reduce the risk of cardiovascular disease.” He said.
The British Heart Foundation’s scientific and medical officer Prof Bryan Williams welcomed the findings, not including the research, but said there was a need for more research.
He said: “There is great interest in studies showing that zone vaccine can reduce the risk of cardiovascular event, but this analysis is based on observational studies that cannot show a great deal of reason and results.
“We know that zones may cause inflammation in the body and that inflammation is a criminal that can lead to heart attacks and paralysis under many heart and circulatory conditions.
“Vaccination can be protective by preventing zone. However, more research is needed to understand interesting consequences, especially in young people. For a wider age group, more evidence will be required before the zone vaccine is recommended.”
Findings came as nhs England said From next week, 300,000 more people will be suitable for zona jab.
People who are appropriate from September 1 are 18 to 49 years old with a seriously weakened immune system. The NHS expanded people over the age of 50 with a seriously weakened immune system.
